The MRTX Paradox: Analysts Bullish But Forecast -13.22% Fall
July 26, 2018 at 08:20 AM EDT
Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Mirati Therapeutics Inc (MRTX). The average 12-month price target for MRTX averaging the work of 6 analysts reveals an average price target of $49.33/share..